12:26 , Oct 19, 2018 |  BC Extra  |  Financial News

Ahead of Phase II, TP raises $80M mezzanine round

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study...
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Cryptosporidium Cell culture and mouse studies identified two compounds that could help treat Cryptosporidium infections. Screening of 12,000 approved or investigational compounds in a C. parvum-infected human cell line identified two compounds, VB-201 and ASP7962,...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Genentech reports ORR of 77.4% for entrectinib in pooled analysis of ROS1-positive NSCLC patients

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from an integrated analysis of 53 patients with locally advanced or metastatic c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)-positive non-small cell lung cancer (NSCLC) in...
15:21 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample and cell culture studies suggest inhibiting BDNF-TrkB signaling could help treat prostate cancer in African-American patients. In prostate fibroblasts isolated from four African-American patients, levels of BDNF were higher than in...
22:10 , Sep 6, 2018 |  BC Extra  |  Preclinical News

Dual therapy could treat AD -- if it can cross into clinic

Researchers at Massachusetts General Hospital and colleagues found concurrently inducing neurogenesis and raising neuroprotective brain-derived neurotrophic factor (BDNF) levels could treat Alzheimer's disease, but it's not clear if -- or how -- such strategies could...
17:06 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling TrkB fusion oncogenes and mutations could help predict sensitivity to the TrkA/TrkB/TrkC inhibitor larotrectinib in patients with blood cancers. Genomic sequencing of 7,311 patients with hematologic malignancies identified one TrkA, one TrkB and...
15:55 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell and rat studies identified three TrkA/TrkB/TrkC inhibitors that could help treat pain. Screening of a small molecule library in cell-based activity assays yielded three analogs of a core scaffold -- a piperidine-pyridine compound,...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus area...
16:06 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest a TrkB-agonizing BDNF peptide could help treat demyelination diseases. In a mouse model of CNS demyelination, intracerebroventricular infusion of a previously reported tricyclic BDNF peptide agonist of TrkB (EC50 = 11...